Feldan Therapeutics news

On June 13th 2019, Anges Québec celebrated its 10th anniversary as part of the annual Rendez-vous 2019, the event that brings together angel investors, portfolio companies, venture capital ecosystem players and partner-sponsors. The 2019 edition was made possible by its major partner Investissement Québec, as well as its partners Fonds de solidarité FTQ, Intact Insurance, Mercer, Novacap, Fondaction and LOK North America.

On this occasion, the Anges Québec

Feldan Therapeutics, a biopharmaceutical company that develops therapeutics based on its proprietary intracellular delivery platform, announced today it was awarded funding by the Cystic Fibrosis Foundation to pursue the development of the Feldan Shuttle technology as a pulmonary delivery agent for cystic fibrosis (CF).

The award is part of the Cystic Fibrosis Foundation’s US$500 million Path to a Cure initiative to accelerate treatments for the underlying

Congratulations to the team at NIH Common Fund’s Somatic Cell Genome Editing (SCGE) program for&nbs

Feldan Therapeutics, a biotechnology company that develops therapeutics based on the intracellular delivery of proteins and peptides, announces the appointment of Dr. David J. Mazzo and Dr. Iain D. Dukes as independent members of its board of directors.

“We are pleased to welcome Drs. Mazzo and Dukes to our board. They are two highly accomplished biopharmaceutical executives who bring many years of operational, strategic and financing expertise to Feldan,” said Franç

Feldan Therapeutics, a biotechnology company focusing on the development of therapeutics based on the intracellular delivery of proteins and peptides, announces the creation of a scientific advisory board and the appointment of an Acting Vice-President, Drug Development.

“I am glad to welcome a group of highly experienced scientists having extensive clinical development and executive management experience on our scientific advisory board, which will be pivotal in providing our t